The histopathological assessment and scoring approach were performed in accordance with validated methods previously described in similar ischemia-reperfusion studies 10,14

(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)

People with malabsorption are more likely to have B12 deficiency
included for metabolic research completeness
Serving Size: 1 Capsule Servings Per Container: 60 Body Protective Compound 500mcg -(as BPC-157 Arginate Salt) Salcaprozate Sodium (SNAC) 1.5mg Other Ingredients: cellulose, magnesium stearate, silicone dioxide
Bio-Boost along with other brand names and generic MIC+B12 usually have the same strenght, 25mg/50mg/50mg/1mg